Business Description
Merck & Co Inc
NAICS : 325412
SIC : 2834
ISIN : US58933Y1055
Compare
Compare
Traded in other countries / regions
MRK.USA0QAH.UKMRCK34.Brazil6MK.GermanyMRK.ArgentinaMRK.MexicoMRK.AustriaMRK.PeruMRK.ChileMRK.FranceMRK.SwitzerlandMRK.RomaniaMRK.Ukraine Description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.17 | |||||
| Equity-to-Asset | 0.37 | |||||
| Debt-to-Equity | 0.95 | |||||
| Debt-to-EBITDA | 3.64 | |||||
| Interest Coverage | 6.4 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 4.03 | |||||
| Beneish M-Score | -2.94 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 15.4 | |||||
| 3-Year EBITDA Growth Rate | 23.9 | |||||
| 3-Year EPS without NRI Growth Rate | 37.2 | |||||
| 3-Year FCF Growth Rate | 14 | |||||
| 3-Year Book Growth Rate | 21.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 14.2 | |||||
| Future 3-5Y Total Revenue Growth Rate | 3.87 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.06 | |||||
| 9-Day RSI | 46.22 | |||||
| 14-Day RSI | 48.9 | |||||
| 6-1 Month Momentum % | 2.67 | |||||
| 12-1 Month Momentum % | 16.69 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.28 | |||||
| Quick Ratio | 1.03 | |||||
| Cash Ratio | 0.27 | |||||
| Days Inventory | 133.6 | |||||
| Days Sales Outstanding | 62.62 | |||||
| Days Payable | 84.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.7 | |||||
| Dividend Payout Ratio | 2.36 | |||||
| 3-Year Dividend Growth Rate | 7.4 | |||||
| Forward Dividend Yield % | 2.73 | |||||
| 5-Year Yield-on-Cost % | 4.07 | |||||
| Shareholder Yield % | 2.47 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 72.96 | |||||
| Operating Margin % | 10.95 | |||||
| Net Margin % | 5.34 | |||||
| ROE % | 7.1 | |||||
| ROA % | 2.9 | |||||
| ROIC % | 4.81 | |||||
| ROC (Joel Greenblatt) % | 27.92 | |||||
| ROCE % | 7.65 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 87.16 | |||||
| Forward PE Ratio | 12.61 | |||||
| PE Ratio without NRI | 87.16 | |||||
| Shiller PE Ratio | 32.27 | |||||
| PEG Ratio | 7.03 | |||||
| PS Ratio | 4.64 | |||||
| PB Ratio | 6.98 | |||||
| Price-to-Free-Cash-Flow | 24.97 | |||||
| Price-to-Operating-Cash-Flow | 17.94 | |||||
| EV-to-EBIT | 46.87 | |||||
| EV-to-Forward-EBIT | 11.61 | |||||
| EV-to-EBITDA | 29.58 | |||||
| EV-to-Forward-EBITDA | 10.16 | |||||
| EV-to-Revenue | 5.15 | |||||
| EV-to-Forward-Revenue | 4.78 | |||||
| EV-to-FCF | 27.74 | |||||
| Price-to-Projected-FCF | 2.09 | |||||
| Price-to-Median-PS-Value | 1.1 | |||||
| Price-to-Peter-Lynch-Fair-Value | 10.73 | |||||
| Earnings Yield (Greenblatt) % | 2.13 | |||||
| Forward Rate of Return (Yacktman) % | 11.68 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Merck & Co Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 55,572.273 | ||
| EPS (TTM) (€) | 1.275 | ||
| Beta | 0.27 | ||
| Volatility % | 20.23 | ||
| 14-Day RSI | 48.9 | ||
| 14-Day ATR (€) | 1.201694 | ||
| 20-Day SMA (€) | 100.925 | ||
| 12-1 Month Momentum % | 16.69 | ||
| 52-Week Range (€) | 88 - 108.8 | ||
| Shares Outstanding (Mil) | 2,537.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Merck & Co Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Merck & Co Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Merck & Co Inc Frequently Asked Questions
What is Merck & Co Inc(FRA:6MK)'s stock price today?
The current price of FRA:6MK is €100.20. The 52 week high of FRA:6MK is €108.80 and 52 week low is €88.00.
When is next earnings date of Merck & Co Inc(FRA:6MK)?
The next earnings date of Merck & Co Inc(FRA:6MK) is 2023-10-27 Est..
Does Merck & Co Inc(FRA:6MK) pay dividends? If so, how much?
The Dividend Yield %  of Merck & Co Inc(FRA:6MK) is 2.7% (As of Today), Highest Dividend Payout Ratio of Merck & Co Inc(FRA:6MK) was 2.36. The lowest was 0.44. And the median was 1.09. The  Forward Dividend Yield % of Merck & Co Inc(FRA:6MK) is 2.73%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers